Anatomical and Functional Outcomes of Vitrectomy with/without Intravitreal Methotrexate Infusion for Management of Proliferative Vitreoretinopathy Secondary to Rhegmatogenous Retinal Detachment

Table 6

Review of studies on PPV for proliferative vitreoretinopathy complicating rhegmatogenous retinal detachment.

Author	PVR grade	Surgical technique	No. of eyes	Retinal reattachment (%)	Final BCVA
Lewis et al. [10]	23% C1-C3	91.3% PPV + 14% C3F8	81	81% (single surgery)	85% ≥ 5/200
	77% D1-D3	8.6% PPV + silicone oil		90% (additional surgeries)
Lewis and Aaberg [11]	19% C3	78% PPV + C3F8	37	68% (single surgery)	59% ≥ 5/200
	81% D1-D3	22% PPV + silicone oil		73% (additional surgeries)
				13% (attachment posterior to scleral buckle)
Silicone Study [12]	PVR C or higher	PPV + C3F8/silicone oil	131 (no prior PPV)	68.5%	44% ≥ 5/200
			134 (prior PPV)	67%	35.5% ≥ 5/200
Asaria et al. [18]	At high risk of PVR	PPV + SF6/C3F8/silicone oil	87 (placebo arm)	71.2%	Stable 12.6%
					Better 45.9%
					Worse 41.3%
Charteris et al. [27]	PVR C	PPV + silicone oil	78 (placebo arm)	51% (single surgery)	∼2 lines gain
Grigoropoulos et al. [26]	PVR C	PPV + C3F8/silicone oil	304	51% (single surgery)	Stable 24%
				72% (additional surgeries)	Better 45%
					Worse 29%
Wickham et al. [29]	86% No PVR	PPV + SF6/C3F8/silicone oil	288 (placebo arm)	86.8% (single surgery)	—
De silva et al. [9]	PVR C	6% PPV + C3F8	145	68%	76% improved or stable
		94% PPV + silicone oil
Lam et al. [28]	PVR C	PPV + silicone oil	147	81.6%	∼3 lines gain
Current study, 2020	41.5% PVR C	9% PPV + C3F8	42 (PVR C)	74% (single surgery)	4 lines mean gain 54% ≥ 0.1, 11% ≥0.4
	35% high risk of PVR	91% PPV + silicone oil	35 (high risk of PVR)	77% (single surgery)
	24% no risk of PVR		24 (no risk of PVR)	96% (single surgery)

BCVA, best-corrected visual acuity; C3F8, octafluoropropane; No., number; PPV, pars plana vitrectomy; PVR, proliferative vitreoretinopathy; SF6, sulfurhexafluoride.